Intravenous tPA Delays Door-To-Puncture Time in Acute Ischemic Stroke with Large Vessel Occlusion.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 03 12 2020
revised: 25 02 2021
accepted: 01 03 2021
pubmed: 18 4 2021
medline: 1 6 2021
entrez: 17 4 2021
Statut: ppublish

Résumé

Although intravenous thrombolysis (IVT) is recommended among acute ischemic stroke (AIS) patients secondary to large vessel occlusion (LVO) undergoing mechanical thrombectomy (MT), time delays with bridging therapy (IVT prior to MT) and its potential benefit remains unclear. We compared the time delays and clinical outcomes among AIS SECONDARY TO LVO patients treated with bridging therapy or direct MT (dMT) at a comprehensive stroke center (CSC). We performed a retrospective analysis of prospectively collected data of AIS secondary to LVO patients admitted between 2012 and 2017 at a large volume CSC. AIS secondary to LVO patients arriving directly from field to CSC within 4.5 h were included. Demographic characteristics, clinical and radiological data, treatment and procedural information were extracted and analyzed. Among 777 AIS secondary to LVO patients treated with MT, 237 patients (156 dMT, 81 bridging therapy) were included. Mean age was 70.3 year-old, median NIHSS score was 18, and door-to-needle time was 40 min (IQR 31-56 min). The median door-to-puncture (DTP) time was 22 min longer in bridging therapy group in comparison to dMT group, 74 vs 52 min (p<0.001). Additionally, no difference was observed between the groups for successful recanalization or functional independence. At a large volume CSC, bridging therapy (vs. dMT) was observed to have a longer DTP time without any difference in successful recanalization or clinical outcomes.

Identifiants

pubmed: 33865227
pii: S1052-3057(21)00135-X
doi: 10.1016/j.jstrokecerebrovasdis.2021.105732
pii:
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105732

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None

Auteurs

Kunakorn Atchaneeyasakul (K)

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

Shashvat Desai (S)

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

Konark Malhotra (K)

Department of Neurology, Allegheny Health Network, Pittsburgh, PA, United States.

Jaydevsinh Dolia (J)

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

Kavit Shah (K)

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

Jeffrey L Saver (JL)

UCLA Comprehensive Stroke Center, Los Angeles, CA, United States.

Tudor Jovin (T)

Cooper University, Camden, NJ, United States.

Ashutosh P Jadhav (AP)

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Electronic address: jadhav.library@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH